Skip to main content

Table 1 Characteristics of participants by biomarker framework

From: Dynamic changes of CSF sTREM2 in preclinical Alzheimer’s disease: the CABLE study

CharacteristicsStage 0Stage 1Stage 2SNAPP
n24214870199 
Age (years)60.81 ± 9.9560.39 ± 10.4164.19 ± 11.0964.59 ± 10.28< 0.001
Gender (F/M)96 / 14663 / 8531 / 3973 / 1261.000
Education (years)9.96 ± 4.3910.17 ± 4.209.24 ± 4.569.32 ± 4.370.188
APOE ε4 carriers (%)38 (15.70)22 (14.86)18 (25.71)27 (13.57)1.000
CM-MMSE score27.94 ± 2.2527.92 ± 1.9927.41 ± 2.1827.61 ± 2.060.155
CSF biomarker
1–42 (pg/ml)170.41 ± 63.10103.31 ± 7.26102.95 ± 6.31224.78 ± 139.64< 0.001
1–40 (pg/ml)5669.91 ± 1855.054567.68 ± 1906.917379.50 ± 2545.578493.87 ± 2982.58< 0.001
T-tau (pg/ml)135.72 ± 25.95124.98 ± 2.55262.85 ± 104.36241.30 ± 88.10< 0.001
P-tau (pg/ml)33.18 ± 3.8531.49 ± 3.8746.13 ± 10.8446.99 ± 11.37< 0.001
1–42/Aβ1–40 (Median, IQR)0.029 (0.024–0.037)0.024 (0.018–0.032)0.014 (0.011–0.018)0.025 (0.18–0.031)< 0.001
T-tau/Aβ1–42 (Median, IQR)0.84 (0.69–1.03)1.20 (1.02–1.36)2.22 (1.85–3.02)1.13 (0.90–1.58)< 0.001
P-tau/Aβ1–42 (Median, IQR)0.21 (0.17–0.25)0.31 (0.28–0.33)0.42 (0.39–0.51)0.24 (0.19–0.31)< 0.001
sTREM2 (pg/ml)18,000.57 ± 6344.5215,121.87 ± 6396.8518,282.53 ± 7538.9720,814.16 ± 6105.39< 0.001
  1. Categorical variables are reported as numbers and percentages; continuous variables are reported as means ± SDs
  2. Abbreviations: SNAP Suspected non-Alzheimer disease pathology, SD Standard deviations, F Female, M Male, APOE Apolipoprotein E, CM-MMSE China Modified Mini-Mental State Examination, CSF Cerebrospinal fluid; Aβ1–42, amyloid-β1–42; Aβ1–40, amyloid-β1–40; T-tau, total tau; P-tau, phosphorylated tau; sTREM2, soluble TREM2